Assessment of ethnic variation in serum levels of total, complexed and free prostate specific antigen. Comparison of Maori, Pacific Island and New Zealand European populations

Pathology

Volumn 35, Issue 6, 2003, Pages 480-483

  Gray, Marion A ^a   Delahunt, Brett ^a   Fowles, Jefferson R ^b   Weinstein, Philip ^a   Cooke, Russell R ^c   Nacey, John N ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^c Cap and Coast District Health Board ^*  (New Zealand)

Author keywords

fPSA; cPSA; Ethnic variation; Maori; New Zealand European; Pacific Island; Prostate specific antigen; Reference range; tPSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; ETHNIC DIFFERENCE; ETHNOLOGY; EUROPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAORI; NEW ZEALAND; PACIFIC ISLANDS; PROSTATE DISEASE; SCORING SYSTEM; URINARY TRACT DISEASE;

EID: 0346786296     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313020310001619091     Document Type: Article

References (24)

1. Brawer MK, Meyer GE, Letran JL, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52: 372-8.
2. Oesterling JE, Jacobsen SL, Klee GG. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090-5.
3. Saw S, Aw T. Age-related reference intervals for free and total prostate-specific antigen in a Singaporean population. Pathology 2000; 32: 245-9.
4. Smith DS, Carvalhal GF, Mager DE, et al. Use of lower prostate specific antigen cutoffs for prostate cancer screening on black and white men. J Urol 1998; 160: 1732-8.
5. Henderson RJ, Eastham JA, Culkin DJ, et al. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst 1997; 89: 134-8.
6. Vashi AR, Oesterling JE. Percent free prostate-specific antigen: Entering a new era in the detection of prostate cancer. Mayo Clin Proc 1997; 72: 337-44.
7. Kao C. Age-related free PSA, total PSA and free PSA/total PSA ratios: establishment of reference ranges in Chinese males. Anticancer Res 1997; 17: 1361-6.
8. Cooney KA, Strawderman MS, Wojno KJ, et al. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology 2001; 57: 91-6.
9. Anderson JR, Strickland D, Corbin D, et al. Age-specific reference ranges for serum prostate-specific antigen. Urology 1995; 46: 54-7.
10. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57.
11. Lodding P, Aus G, Bergahl S, et al. Characteristics of screening detected prostate cancer in Men 50 to 66 years old with 3 to 4ng/mL Prostate Specific Antigen. J Urol 1998; 159: 899-903.
12. Crawford DE, DeAntoni P, Etzioni R, et al. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. Urology 1996; 47: 863-9.
13. Bangma CH, Kranse R, Blijenberg BG, et al. The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. Urology 1995; 46: 773-8.
14. DeAntoni EP, Crawford ED, Oesterling JE, et al. Age and race-specific reference ranges for prostate-specific antigen from a large community based study. Urology 1996; 48: 234-9.
15. Catalona WJ, Partin AW, Slawin KM, et al. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology 2000; 55: 372-6.
16. Gelmann EP, Chia D, Pinsky PF, et al. PLCO Screening Trial Investigators. Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology 2001; 58: 561-6.
17. Statistics New Zealand: Census Tatauranga. 2001 Census. [data online]. Available from: URL: http://www.stats.govt.nz/; 2002.
18. Moore MP, Lunt H. Diabetes in New Zealand. Diabetes Res Clin Pract 2000; 50 Suppl. 2: S65-71.
19. New Zealand Health Information Service. Prostatectomy operations performed in publicly funded hospitals between 1997-1999. [Unpublished data. 2002.]
20. Nacey JN, Morum P, Delahunt B. Analysis of the prevalence of voiding symptoms in Maori, Pacific Island and Caucasian New Zealand men. Urology 1995; 46: 506-11.
21. Malcolm L. Inequities in access to and utilisation of primary medical care services for Maori and low income New Zealanders. NZ Med J 1996; 109: 356-8.
22. Davis P, Lay-Yee R, Maingay S, Gribben B. Patterns of general practitioner usage among Pacific people: indicative results from the Waikato Medical Care Survey 1991-2. NZ Med J 1997; 110: 335-6.
23. Sporle A, Pearce N. Impact of changes in the death registration process upon Maori mortality statistics. NZ Med J 1999; 112: 411-2.
24. Sporle A, Pearce N, Davis P. Social class mortality differences in Maori and non-Maori men aged 15-64 during the last two decades. NZ Med J 2002; 115: 127-31.